See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"Science is not only a disciple of reason but, also, one of romance and passion."
- Stephen Hawking
Quick Explanation
Copied
Jiaen Wei — evidence-weighted scientific critique (based on the provided publication record)
From the available record, Jiaen Wei’s output shown here is dominated by review articles in cancer signaling pathways and marine natural products (e.g., PI3K/Akt, MAPK/ERK, NF-κB), plus at least one primary research article (TRAF6 inhibitor discovery) and at least one network pharmacology/docking preprint.
Evidence strength: reviews are useful for synthesis, but they cannot by themselves establish causal mechanisms; the key scientific weakness to check is whether “direct target” claims are supported by binding/biochemical validation rather than only pathway-level or phenotypic readouts. For deeper target-level scrutiny, examine primary studies that validate direct interactions and quantify effect sizes under controlled, comparable conditions.
Long Explanation
Author Review: Jiaen Wei
Scope of evidence used in this review: the publication record and one detailed research-data entry you provided (not additional unseen papers). Primary emphasis is on: (i) review synthesis in cancer signaling and marine natural products, and (ii) whether “mechanism” claims likely rest on direct biochemical evidence vs literature-level pathway aggregation.
2) Evidence-based review of selected works (mechanism claims vs validation)
2.1 Marine compounds targeting PI3K/Akt in cancer — review synthesis (2020)
The provided record describes the work as a review cataloging marine-derived compounds targeting the PI3K/Akt signaling pathway in cancer therapy, covering 27 marine compounds and mapping sources/structures/targets (where known) and reported preclinical activities. The research-data entry highlights an important recurring theme: only a subset have clearly identified direct protein targets, while for most compounds the mechanism may be inferred from pathway-level effects and heterogeneous experimental readouts. This is the core scientific strength of the review (gap mapping), but also a built-in limitation for causal claims (target validation may be incomplete across the literature it aggregates).
What this implies about Jiaen Wei’s scientific contribution
Strength: Reviews can be high value when they map evidence gaps and specify what would falsify or refine mechanism hypotheses (e.g., lack of direct target identification). In this record, that gap focus is explicitly stated.
Limitation: If the author’s role is primarily synthesis, then “mechanism” confidence is constrained by the underlying literature’s experimental quality, standardization, and target-validation rigor. Pathway inhibition in cell/animal models does not necessarily prove direct binding or on-target causality.
Figure: evidence type vs mechanistic confidence (conceptual map grounded in the provided description)
Note: This is a qualitative proxy to visualize the review’s stated emphasis (direct target identification being rarer than inferred pathway effects). It is not derived from new measurements.
2.2 Other topic-aligned reviews (2021–2022): PI3K/Akt, MAPK/ERK, NF-κB, microRNA
The provided record also shows additional review-type publications spanning signaling pathways (e.g., MAPK/ERK, NF-κB) and regulatory layers (e.g., microRNA-33a in malignant cells). These are consistent with a research style centered on cell signaling pathway synthesis and natural-product pharmacology.
MAPK signaling pathway-targeted marine compounds in cancer therapy (review, 2021) —
Role of microRNA-33a in malignant cells (review, 2020) —
Critical check you should apply (to any review-based author profile)
Direct vs indirect mechanism: Do the cited studies include direct biochemical or biophysical evidence (binding, enzymatic activity, ubiquitination assays, etc.) or only pathway-level readouts?
Consistency across models: Are effects robust across cell lines and in vivo systems, or does the review rely on a narrow set of model-dependent results?
Quantitative comparability: Are effect sizes comparable (assay conditions, exposure times, concentrations)? Reviews often aggregate non-uniform experimental conditions.
2.3 Primary research signal (2021): TRAF6 inhibitor for hepatocellular carcinoma
The provided record includes at least one primary research paper about identifying a TRAF6 inhibitor for hepatocellular carcinoma. This is scientifically important because primary experimental work can, in principle, provide direct mechanistic evidence (e.g., enzyme inhibition, target engagement proxies, pathway downstream validation), unlike pure literature reviews.
Rigor questions to ask when reading the full paper
Does the paper test direct enzymatic inhibition (or other direct target engagement metrics) rather than only observing downstream signaling changes?
Are controls adequate to distinguish on-target TRAF6 effects from off-target cytotoxicity?
Are dose–response curves and replicates clearly reported (and do results reproduce across independently prepared experiments)?
The provided record includes a preprint using network pharmacology and molecular docking to infer mechanisms of a multi-herb formulation for gastritis. Such work is potentially valuable for hypothesis generation, but mechanistic credibility depends on follow-up experimental validation and the degree to which docking/network predictions are filtered for plausibility.
Domain coherence: The record is consistently clustered around cancer-related signaling pathways and marine/natural-product pharmacology. Topic coherence often helps authors build a focused reading and synthesis pipeline.
Gap awareness in reviews: The PI3K/Akt marine compounds review description explicitly highlights limited direct target identification for many compounds, which is exactly the kind of limitation that prevents overclaiming causal mechanisms.
At least one primary research paper: Presence of a TRAF6 inhibitor primary study (not only reviews) suggests the author can participate in experimental work where causal inference may be possible if methods are rigorous.
What is likely weaker / where bias or uncertainty could enter
Review-by-itself ceiling: Reviews can’t exceed the experimental validity of the studies they summarize. If many included studies rely on pathway readouts without direct binding or genetic causal tests, mechanism claims will remain probabilistic.
Heterogeneity & reproducibility risk: Even within a focused pathway (e.g., PI3K/Akt), assays and model conditions frequently differ. Without standardized comparison, effect sizes and mechanistic claims become less reliable.
Publication bias risk (general): The review description itself notes potential biases such as reliance on published literature and possible publication bias. This is a known epistemic weakness for literature synthesis, especially in natural product pharmacology where positive findings are preferentially published.
Model/context dependence: For cancer signaling, context (cell line genotype, pathway rewiring, microenvironment) can drive discordant results. A robust author should explicitly separate “works in some models” from “works generally.”
Figure: evidence hierarchy implied by the provided record
This is a framework to help you interpret how author roles (review vs primary vs computational) typically constrain mechanistic confidence; you should still read each methods section.
4) What would most change this assessment (disconfirming information)
If the TRAF6 inhibitor paper includes strong direct target engagement assays (e.g., biochemical inhibition/biophysical binding) and demonstrates on-target specificity, that would raise the rigor score substantially.
If the marine signaling reviews rely heavily on studies with weak mechanistic validation (only pathway readouts, limited controls), the practical mechanistic confidence of the author’s overall contribution would decrease.
If additional primary studies (not shown here) exist and show reproducible, quantitative, directly validated mechanisms, then the current “review-dominant” characterization would need updating.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A “single master pathway” model where most marine compounds act primarily through PI3K/Akt alone is unlikely if direct targets are rare and effects vary by model context; a multi-target/off-pathway reality better fits the stated gap.
Assuming pathway inhibition automatically implies direct binding would be a conceptual error; many compounds could be upstream, parallel, or cytotoxic-independent modulators without direct target engagement.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight